Witfire

Unicycive OLC CRL: The CMC Failure Behind a Biotech Selloff

Unicycive OLC received a second FDA CRL over third-party manufacturing deficiencies. The case shows why CMC risk now drives ...
Witfire

AlzeCure ACD856 QuantumCell Deal: $2.2B Risk Transfer in Alzheimer’s

AlzeCure licensed NeuroRestore ACD856 to QuantumCell in a deal worth over $2.2B. The real story is not proof, but Alzheimer’s ...
Witfire

Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell

Viridian’s Lumvoa approval breaks Tepezza’s TED monopoly. Inside the label, Phase 3 data, safety risks, payer hurdles and ...
Witfire

FDA Issues CRL to Sobi for NASP in Uncontrolled Gout

FDA Issues CRL to Sobi for NASP in Uncontrolled Gout, but the letter did not attack the clinical case. It attacked ...
Witfire

Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3

SigHT is formally a long-term observational study. Strategically, its timing points to something larger: Tanabe is building a ...
Witfire

Revolution Medicines Built a $4.3 Billion Wall Around Daraxonrasib

Revolution Medicines built a $4.3B liquidity wall around daraxonrasib. Inside its Phase 3 data, Royalty Pharma terms, ...
thewitfire

Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice

Four months after FDA refused to file Moderna’s application, its vaccine advisers unanimously supported its benefit-risk profile in adults aged 50–64 and again in adults aged 65 and older. Same ...
thewitfire

FDA & Regulatory Intelligence

Viridian’s Lumvoa Broke Tepezza’s Monopoly. Now Viridian Has to Prove It Can Sell | Witfire Elite View Witfire Elite Competitive Strategy Case Studies Launch Execution Long Read Pharma Market Case ...